HC Wainwright Reaffirms “Buy” Rating for Advaxis, Inc. (ADXS)
HC Wainwright reissued their buy rating on shares of Advaxis, Inc. (NASDAQ:ADXS) in a research report report published on Wednesday morning. HC Wainwright currently has a $23.00 target price on the biotechnology company’s stock.
A number of other equities analysts have also weighed in on ADXS. BidaskClub lowered shares of Advaxis from a hold rating to a sell rating in a report on Monday, July 31st. ValuEngine lowered shares of Advaxis from a sell rating to a strong sell rating in a report on Tuesday, August 8th. Finally, Cantor Fitzgerald restated a buy rating and issued a $19.00 price objective on shares of Advaxis in a report on Monday, September 25th.
Advaxis (NASDAQ ADXS) traded up $0.21 during mid-day trading on Wednesday, hitting $3.39. 552,100 shares of the stock traded hands, compared to its average volume of 703,197. Advaxis has a 1 year low of $3.04 and a 1 year high of $10.69.
Advaxis (NASDAQ:ADXS) last announced its quarterly earnings data on Monday, September 11th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.27). Advaxis had a negative return on equity of 93.54% and a negative net margin of 655.66%. The firm had revenue of $3.05 million during the quarter, compared to analysts’ expectations of $3.43 million. sell-side analysts predict that Advaxis will post -2.21 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “HC Wainwright Reaffirms “Buy” Rating for Advaxis, Inc. (ADXS)” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.watchlistnews.com/hc-wainwright-reaffirms-buy-rating-for-advaxis-inc-adxs/1696210.html.
In related news, CFO Sara Bonstein sold 12,734 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total value of $40,621.46. Following the completion of the transaction, the chief financial officer now directly owns 244,504 shares in the company, valued at approximately $779,967.76. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 600,000 shares of the business’s stock in a transaction on Wednesday, October 11th. The shares were sold at an average price of $4.30, for a total transaction of $2,580,000.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,872,291 shares of company stock valued at $8,163,810. 7.21% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Voya Investment Management LLC raised its stake in Advaxis by 20.3% during the 2nd quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 2,975 shares during the last quarter. Cutler Capital Management LLC purchased a new stake in Advaxis during the 2nd quarter valued at $130,000. Northern Capital Management LLC raised its stake in Advaxis by 14.6% during the 2nd quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 2,650 shares during the last quarter. Stonebridge Capital Management Inc. purchased a new stake in Advaxis during the 2nd quarter valued at $146,000. Finally, PNC Financial Services Group Inc. raised its stake in Advaxis by 18.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock valued at $168,000 after buying an additional 4,000 shares during the last quarter. Institutional investors and hedge funds own 48.00% of the company’s stock.
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.